202 related articles for article (PubMed ID: 36743041)
1. Click Chemistry-Generated Auristatin F-Linker-Benzylguanine for a SNAP-Tag-Based Recombinant Antibody-Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells.
Huysamen AM; Fadeyi OE; Mayuni G; Dogbey DM; Mungra N; Biteghe FAN; Hardcastle N; Ramamurthy D; Akinrinmade OA; Naran K; Cooper S; Lang D; Richter W; Hunter R; Barth S
ACS Omega; 2023 Jan; 8(4):4026-4037. PubMed ID: 36743041
[TBL] [Abstract][Full Text] [Related]
2. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
3. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.
Woitok M; Klose D; Di Fiore S; Richter W; Stein C; Gresch G; Grieger E; Barth S; Fischer R; Kolberg K; Niesen J
Onco Targets Ther; 2017; 10():3313-3327. PubMed ID: 28740407
[TBL] [Abstract][Full Text] [Related]
5. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800
[TBL] [Abstract][Full Text] [Related]
6. Applications of SNAP-tag technology in skin cancer therapy.
Padayachee ER; Adeola HA; Van Wyk JC; Nsole Biteghe FA; Chetty S; Khumalo NP; Barth S
Health Sci Rep; 2019 Feb; 2(2):e103. PubMed ID: 30809593
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
8. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
[TBL] [Abstract][Full Text] [Related]
9. One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology.
Hussain AF; Heppenstall PA; Kampmeier F; Meinhold-Heerlein I; Barth S
Nat Protoc; 2019 Nov; 14(11):3101-3125. PubMed ID: 31605098
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
11. Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer.
Padayachee ER; Biteghe FAN; Malindi Z; Bauerschlag D; Barth S
Transfus Med Hemother; 2017 Sep; 44(5):303-310. PubMed ID: 29070975
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
13. EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing.
Jäger S; Dickgiesser S; Tonillo J; Hecht S; Kolmar H; Schröter C
Biol Chem; 2022 Apr; 403(5-6):525-534. PubMed ID: 34535048
[TBL] [Abstract][Full Text] [Related]
14. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
15. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
16. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
[TBL] [Abstract][Full Text] [Related]
17. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
18. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
19. Targeting and Covalently Immobilizing the EGFR through SNAP-Tag Technology for Screening Drug Leads.
Fu J; Jia Q; Liang P; Wang S; Zhou H; Zhang L; Gao C; Wang H; Lv Y; Han S
Anal Chem; 2021 Aug; 93(34):11719-11728. PubMed ID: 34415741
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]